EP4285899A1 - Préparation orale contenant un inhibiteur de jak ou un sel de celui-ci ou une forme cristalline de celui-ci, son procédé de préparation et son application - Google Patents

Préparation orale contenant un inhibiteur de jak ou un sel de celui-ci ou une forme cristalline de celui-ci, son procédé de préparation et son application Download PDF

Info

Publication number
EP4285899A1
EP4285899A1 EP22745081.4A EP22745081A EP4285899A1 EP 4285899 A1 EP4285899 A1 EP 4285899A1 EP 22745081 A EP22745081 A EP 22745081A EP 4285899 A1 EP4285899 A1 EP 4285899A1
Authority
EP
European Patent Office
Prior art keywords
oral preparation
preparation according
compound
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22745081.4A
Other languages
German (de)
English (en)
Inventor
Zheng Wang
Peng Gao
Tingting Yu
Yujun He
Meiyue SHEN
Liwei MU
Jingjing Liu
Lixiu SHI
Degang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuhai United Laboratories Co Ltd
Original Assignee
Zhuhai United Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuhai United Laboratories Co Ltd filed Critical Zhuhai United Laboratories Co Ltd
Publication of EP4285899A1 publication Critical patent/EP4285899A1/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present application belongs to the field of pharmaceutical preparations, and, in particular, relates to an oral preparation of a class of [1,2,4] triazolo [1,5-a] pyridine compounds and isomers or pharmaceutically acceptable salts or crystal forms thereof, as well as preparation method and application thereof.
  • the oral preparation has the characteristics of rapid dissolution.
  • JAK kinases are a family of intracellular non-receptor tyrosine kinases.
  • the kinase family has four members: JAK1, JAK2, JAK3, and TYK2.
  • JAK1, JAK2, and TYK2 are all expressed in human histiocyte, and JAK3 is mainly expressed in hematopoietic histiocyte.
  • JAK belongs to a tyrosine kinase family involved in inflammation, autoimmune diseases, proliferative diseases, transplant rejection (or graft versus host disease), diseases involving impaired cartilage turnover, congenital cartilage malformations, and/or diseases related to excessive IL6 secretion.
  • JAK signaling pathway inhibiting the JAK signaling pathway is believed to regulate multiple signaling pathways related to inflammation, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impaired cartilage turnover, congenital cartilage malformations, and/or diseases related to excessive IL-6 secretion.
  • JAK-STAT Signal Transducers and Activators of Transcription
  • the JAK-STAT pathway can transmit extracellular signals from various cytokines, interferons, most interleukins, and endocrine factors to the cell nucleus, and is responsible for the expression of protein coding genes.
  • cytokines bind to their receptors
  • members of the JAK family undergo self phosphorylation and/or mutual phosphorylation, followed by phosphorylation of STATs and migration to the nucleus to regulate transcription.
  • the JAK-STAT pathway is one of the main research directions in the pathogenesis of rheumatoid arthritis (RA), and studies have shown that IFN- ⁇ , TNF- ⁇ , IL-1 ⁇ , IL-2, IL-4, IL-6, IL-7, IL-9, IL-10, IL-15, IL-17, IL-21, and many other cytokines play an important role in the pathogenesis of RA by influencing the JAK-STAT pathway.
  • This signaling pathway is continuously activated during RA, participating in the proliferation of synovial cells and the release of inflammatory cytokines. Therefore, targeted blockade of the JAK-STAT pathway can achieve the goal of regulating cell activity and improving the pathological process of RA.
  • WO/2020/038457 discloses a series of JAK kinase inhibitors that satisfy the general formula I of [1,2,4]triazolo[1,5-a] pyridine compounds and isomers or pharmaceutically acceptable salts thereof:
  • JAK kinase inhibitor It is known that it is a small molecule JAK kinase inhibitor with significant JAK kinase inhibitory activity and high selectivity, and it is expected that these compounds may be used for the treatment of rheumatoid arthritis.
  • the oral preparations of the JAK kinase inhibitor has not yet been publicly disclosed.
  • a purpose of the present application is to provide an oral preparation with rapid dissolution and good stability, and the preparation process of the oral preparation is simple, suitable for industrial large-scale production.
  • the present application provides an oral preparation comprising a JAK inhibitor and a pharmaceutical excipient, wherein the JAK inhibitor includes a compound of formula (I), an isomer thereof, pharmaceutically acceptable salts thereof, or crystal form thereof: wherein,
  • the pharmaceutical excipients include a filler, a disintegrant, an adhesive, a lubricant or a surfactant, or a combination of two or more thereof.
  • the compound of formula (I), isomers thereof, or pharmaceutically acceptable salts thereof is selected from wherein,
  • JAK inhibitors include the following compounds, their isomers, or pharmaceutically acceptable salts thereof
  • the compound of formula (I), isomers thereof, or pharmaceutically acceptable salts thereof is selected from
  • the oral preparation includes one or more fillers.
  • the oral preparation includes one or more disintegrants.
  • the oral preparation includes one or more adhesives.
  • the oral preparation further includes one or more lubricants.
  • the oral preparation further includes one or more surfactants.
  • the oral preparation includes one or more fillers and one or more disintegrants.
  • the oral preparation includes one or more fillers, one or more disintegrants, and one or more adhesives.
  • the oral preparation includes one or more fillers, one or more disintegrants, one or more adhesives, and one or more lubricants.
  • the oral preparation includes one or more fillers, one or more disintegrants, one or more adhesives, one or more lubricants, and one or more surfactants.
  • the filler is selected from microcrystalline cellulose, lactose, pre-gelatinized starch or anhydrous dicalcium phosphate, or a combination of two or more of them.
  • the disintegrant is selected from cross-linked carboxymethyl cellulose sodium, carboxymethyl starch sodium, cross-linked polyvinylketone or dry starch, or a combination of two or more of them.
  • the adhesive is selected from a carboxymethyl cellulose, hydroxypropyl cellulose, polyvinylketone, methyl cellulose, or ethyl cellulose, or a combination of two or more of them.
  • the lubricant is selected from magnesium stearate, micronized silica gel, talc powder, hydrogenated vegetable oil, polyethylene glycol or sodium dodecyl sulfate, or a combination of two or more of them.
  • the surfactant is sodium dodecyl sulfate.
  • the present application provides an oral preparation comprising compound (S)-N-(5-(2-(2,2-difluorocyclopropane carbonyl)-2-azaspiro[3.5]non 7-yl)-[1,2,4]triazole[1,5-a]pyridin-2-yl) cyclopropane formamide of formula (II) or pharmaceutically acceptable salts thereof, as well as one or more fillers, one or more disintegrants, one or more adhesives, one or more lubricants, and one or more surfactants.
  • crystal form A of the compound of formula (II) or pharmaceutically acceptable salts thereof is A, B, C, or crystal form D.
  • the analytical data of the A-crystal form XRPD diagram of the compound of formula (II) is as follows: No. 2 ⁇ angle (°) Relative strength (%) No. 2 ⁇ angle (°) Relative strength (%) 1 6.91 100.0 18 25.88 8.3 2 10.34 13.7 19 26.18 4.9 3 12.21 64.7 20 26.93 2.8 4 13.69 23.1 21 27.52 18.9 5 14.44 9.8 22 28.73 2.6 6 16.11 3.1 23 29.12 8.2 7 17.44 12.2 24 29.92 6.8 8 18.11 18.7 25 31.56 6.9 9 18.76 11.7 26 31.86 9.6 10 19.06 76.7 27 32.43 6.0 11 19.86 32.6 28 32.64 7.2 12 20.59 28.8 29 33.04 2.5 13 22.06 24.8 30 33.30 2.3 14 22.63 6.8 31 34.52 10.0 15 23.49 2.4 32 35.21 3.9 16 24.46 12.0 33 35.56 2.8 17 25.27
  • the analytical data of the B-crystal form XRPD diagram of the compound of formula (II) is as follows: No. 2 ⁇ angle (°) Relative strength (%) No. 2 ⁇ angle (°) Relative strength (%) 1 5.13 65.7 20 26.06 9.0 2 7.34 43.4 21 26.61 4.1 3 10.14 27.3 22 27.03 7.2 4 10.56 23.7 23 27.69 2.0 5 11.46 13.7 24 28.45 2.5 6 11.72 42.7 25 28.97 5.5 7 14.64 2.1 26 29.49 8.8 8 16.67 27.0 27 29.81 2.8 9 16.86 13.6 28 30.41 6.7 10 18.84 22.5 29 30.72 3.4 11 19.14 55.0 30 31.15 3.2 12 20.31 3.7 31 32.00 3.1 13 21.18 100.0 32 32.35 3.0 14 21.78 20.5 33 33.34 3.6 15 22.03 9.3 34 33.65 2.3 16 22.54 14.2 35 37.00 2.5 17 22.96 13.2 36 38.60
  • the analytical data of the C-crystal form XRPD diagram of the compound of formula (II) is as follows: No. 2 ⁇ angle (°) Relative strength (%) No. 2 ⁇ angle (°) Relative strength (%) 1 5.76 19.3 8 18.66 29.0 2 8.92 31.2 9 19.17 22.1 3 11.50 13.9 10 20.26 100.0 4 14.28 11.4 11 22.98 6.2 5 16.35 23.6 12 24.79 24.0 6 17.54 11.4 13 29.77 5.1 7 17.99 7.5
  • the analytical data of the D-crystal form XRPD diagram of the compound of formula (II) is as follows: No. 2 ⁇ angle (°) Relative strength (%) No. 2 ⁇ angle (°) Relative strength (%) 1 7.12 100.0 14 21.42 44.1 2 10.28 12.3 15 21.84 7.9 3 10.68 2.7 16 23.95 3.0 4 12.45 36.0 17 24.50 5.1 5 13.04 7.2 18 25.74 4.3 6 14.28 26.7 19 26.69 4.9 7 14.64 30.4 20 27.24 2.5 8 16.06 3.1 21 28.72 17.0 9 17.30 7.2 22 29.49 5.0 10 17.50 10.8 23 31.80 4.3 11 18.31 16.1 24 34.05 7.8 12 20.54 77.4 25 36.04 6.1 13 20.93 20.5
  • the XRPD diagram of the crystal form A of the compound of formula (II) is shown in FIG. 6 .
  • the XRPD diagram of the crystal form B of the compound of formula (II) is shown in FIG. 8 .
  • the XRPD diagram of the crystal form C of the compound of formula (II) is shown in FIG. 11 .
  • the XRPD diagram of the crystal form D of the compound of formula (II) is shown in FIG. 13 .
  • the pharmaceutically acceptable salt of the active ingredient can be selected from a group consisting of (S)-N-(5- (2-(2,2-difluorocyclopropane carbonyl)-2-azaspiro[3.5]non 7-yl)-[1,2,4]triazole [1,5-a] pyridin-2-yl) cyclopropane formamide or pharmaceutically acceptable salt thereof, with an active ingredient content of 1% to 50%, preferably 5% to 40%, further preferably 6% to 30%, more preferably 8% to 25% of the total weight of the composition. As an exemplary illustration, it can be 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%.
  • the oral preparation provided in the present application may further include one or more of the fillers, disintegrants, adhesives, lubricants, and surfactants.
  • the filler can include, but not limited to, lactose, microcrystalline cellulose, pre-gelatinized starch, anhydrous calcium hydrogen phosphate, calcium sulfate, calcium carbonate, dextrin, maltose, mannitol, sorbitol, trehalose, xylitol, etc.
  • the filler is one or more selected from a group consisting of lactose, microcrystalline cellulose, pre-gelatinized starch, and anhydrous dicalcium phosphate.
  • the filler is a mixture of lactose and microcrystalline cellulose.
  • the content of the filler can be 0% to 78.5%, preferably 10% to 70%, further preferably 20% to 60%, more preferably 30% to 50% of the total weight of the pharmaceutical composition. As an exemplary illustration, it can be 30%, 31.75%, 37.25%, 39.25%, 41.75%, 42.25%, 43.75%.
  • the weight ratio of lactose to microcrystalline cellulose is 0:1, 5:3, 3:1, 1:1, 1:0; and preferably 1:1.
  • disintegrating agents may include, but not limited to, cross-linked carboxymethyl cellulose sodium, carboxymethyl starch sodium, cross-linked polyvinylketone, dry starch, low substituted hydroxypropyl cellulose, alginate, chitosan, and corn starch.
  • the disintegrant in the composition may include, but not limited to, one or more cross-linked carboxymethyl cellulose sodium, carboxymethyl starch sodium, or cross-linked polyvinone.
  • the disintegrant is cross-linked carboxymethyl cellulose sodium.
  • the content of the disintegrating agent in the oral preparation provided in the present application can be 1% to 25%, preferably 2% to 16%, more preferably 4%, 8%, or 12%, of the total weight of the pharmaceutical composition.
  • the adhesive may include, but not limited to, to one or more hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylketone, pre-gelatinized starch, sodium carboxymethyl cellulose, and methyl cellulose.
  • the content of the adhesive is about 0.1% to 5%, preferably 1% to 4%, more preferably 2% to 3%, and most preferably 1.5% (20 mg composition for example, which contains 3 mg of adhesive).
  • the oral preparation provided in the present application may further contain one or more lubricants, such as magnesium stearate, micronized silica gel, talc powder, hydrogenated vegetable oil, polyethylene glycol, and sodium dodecyl sulfate, with a lubricant content of 0.1% to 5%, preferably 0.5% to 3%, and more preferably 1% of the total weight of the composition.
  • lubricants such as magnesium stearate, micronized silica gel, talc powder, hydrogenated vegetable oil, polyethylene glycol, and sodium dodecyl sulfate
  • the oral preparation provided by the present application may further contain one or more surfactants, such as sodium dodecyl sulfate (SDS), with a content of approximately 0.1% to 5%; preferably 1% to 3%; most preferably 2%, based on the total weight of the composition.
  • surfactants such as sodium dodecyl sulfate (SDS), with a content of approximately 0.1% to 5%; preferably 1% to 3%; most preferably 2%, based on the total weight of the composition.
  • a pharmaceutical composition including the following components by weight:
  • a pharmaceutical composition including the following components by weight:
  • the oral preparation of the present application can be prepared using commonly used preparation methods in the field, for example, preparing pharmaceutical composition granules by wet granulation, dry granulation, one-step granulation, and the like, and then tableting.
  • the pharmaceutical composition of the present application can be further prepared into tablets by powder direct pressing method.
  • the filler, disintegrant, adhesive, lubricant or surfactant can be added internally or externally.
  • the filler can be added internally or externally.
  • the disintegrant can be added internally or externally.
  • the adhesive can be added internally or externally
  • the lubricant can be added internally or externally.
  • the surfactant is added internally or externally.
  • the oral preparation of the present application dissolves very quickly and completely.
  • 0.01mol/L hydrochloric acid solution is used as the dissolution medium, preferably 900ml of 0.01mol/L hydrochloric acid solution.
  • the dissolution test of the combination of the present application is carried out at a paddle speed of 50rpm at 37 ⁇ 0.5 °C, with a dissolution rate of 80% or more in 10 minutes or 15 minutes, preferably a dissolution rate of 90% or more in 15 minutes or 20 minutes, and more preferably a dissolution rate be greater than or equal to 95% in 30 minutes or 45 minutes.
  • the oral preparation of the present application is placed in a watch glass and subjected to stability tests under high temperature (60 °C), high humidity (relative humidity 75% ⁇ 1%, 15.5-60 °C), and light (illumination 4500lx ⁇ 500lx) conditions. Samples are taken at 5, 10, and 30 days respectively, and changes in relative substances, content, and dissolution rate are measured using HPLC. The results show that the composition provided by the present application has stable properties, and as are compared 5, 10, 30 days with 0 days, there were no significant differences of influencing factors like the relevant substances, dissolution, and content.
  • the oral preparation of the present application was placed in an environment with a temperature of 40 °C ⁇ 2 °C and a relative humidity of 75% ⁇ 5% for stability evaluation. After being placed for one month, the changes in the relevant substances, content, and dissolution were determined using HPLC method. The results showed that the composition provided by the present application had stable properties, and as compared acceleration for one month with 0 days, there was no significant difference in the relevant substances, dissolution, and content.
  • pharmaceutically acceptable used in the present application refers to compounds, materials, compositions, and/or dosage forms that are within the scope of reliable medical judgment and are suitable for use in contact with human and animal tissues, without excessive toxicity, irritation, allergic reactions, or other issues or complications, and are proportional to a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salt refers to the salt of a compound of the present application, prepared by the discovery of a compound with a specific substituent group and a relatively non-toxic acid or base.
  • alkali addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of alkali in a pure solution or suitable inert solvent.
  • Pharmaceutically acceptable alkali addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts, or similar salts.
  • acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in a pure solution or suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts, which include, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphite, etc; And organic acid salts, including acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; It further includes salts of amino acids such as arginine, as well as salts of organic acids such as glucuronic acid.
  • the "pharmaceutical composition” described in the present application is typically used for oral administration.
  • the pharmaceutical composition used for oral administration may further include sweeteners, flavouring, colorants, coating agents, and/or preservatives to provide palatable formulations.
  • the pharmaceutical composition is in the form of tablets. Tablets can be prepared by pressing or molding. Compressed tablets can be prepared by pressing free flowing active ingredients such as powders or particles in a suitable machine, optionally mixed with adhesives, lubricants, inert diluents, or preservatives. Molded tablets can be prepared by molding in a suitable machine and wetting a mixture of powdered active ingredients with an inert liquid diluent. Tablets can be optionally coated or scored.
  • compositions refers to a method of combining different chemical substances (including active drugs) to produce the final medicinal product.
  • Pharmaceutical preparations include enteral preparations (tablets, capsules), parenteral preparations (liquids, freeze-dried powders), or topical preparations (skin, inhalable).
  • the "pharmaceutically acceptable excipients, carriers, or diluents" of the present application include, but not limited to, any adjuvants, carriers, excipients, retention aids, additives, diluents, preservatives, dyes/colorants, flavoring agents, surfactants, wetting agents, dispersants, suspension aids, stabilizers, isotopes, solvents or emulsifiers licensed by relevant government regulatory authorities as acceptable for human or livestock use.
  • fillers refers to a substance that can improve the compressibility and uniformity of a drug. Fillers include starch, sucrose, dextrin, lactose, pre-gelatinized starch, microcrystalline cellulose, corn starch, dextrose, ethyl cellulose, fructose, maltodextrin, maltose, medium chain triglycerides, anhydrous calcium hydrogen phosphate, calcium sulfate, calcium carbonate, sugar alcohol erythritol, isomaltosol, lactitol, mannitol, sorbitol, trehalose, and xylitol.
  • disintegrating agent refers to an excipient that causes a tablet to rapidly break into small particles in gastrointestinal fluid, mainly used to eliminate the binding force generated by adhesion and/or high compression, thereby causing the tablet to disintegrate in water.
  • Disintegration agents include dry starch, sodium carboxymethyl starch, low substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, cross-linked povidone, microcrystalline cellulose, alginate, sodium alginate, etc.
  • binder refers to an auxiliary material that has inherent viscosity and can impart appropriate viscosity to materials without viscosity or with insufficient viscosity, promoting the bonding of solid powder into larger particles, which helps to make stronger dosage forms. Binders include starch slurry, cellulose derivatives, methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, povidone, gelatin, 50% ⁇ 70% sucrose solution, sodium alginate solution, etc.
  • Lubricant refers to the material that prevents material from accumulating and adhering to the surface of the punch and punch, or adhering to the capsule filling machine.
  • Lubricants can improve the surface characteristics of particles, such as improving the electrostatic distribution on the particle surface, improving the roughness of the particle surface, reducing friction, improving gas selective adsorption, and weakening the van der Waals force between particles.
  • Lubricants include magnesium stearate, micropowder silica gel, talc, hydrogenated vegetable oil, polyethylene glycols, sodium dodecyl sulfate, hydrogenated castor oil, cottonseed oil, behenic acid glyceride, monostearin glyceride, palmitic acid glyceride, medium chain triglyceride, mineral oil, light mineral oil, octyl lauryl alcohol, poloxamer, polyethylene glycol, polyoxyethylene stearate, polyvinyl alcohol, etc.
  • the autoimmune diseases mentioned in the present application refer to rheumatoid arthritis, inflammatory bowel disease (ulcerative colitis, Krohn's disease), systemic lupus erythematosus, dermatomyositis, ankylosing spondylitis, multiple sclerosis, type I diabetes, psoriasis, vitiligo, Sjogren's syndrome, etc., or other inflammatory skin diseases such as atopic dermatitis, eczema, lichen planus, lichen lustre, lichen scleroatrophicus, panniculitis, acne Purulent sweat gland inflammation, etc.
  • Crushed TUL01101, lactose, microcrystalline cellulose, cross-linked carboxymethyl cellulose sodium, carboxymethyl starch sodium, cross-linked polyvinylketone, and substituted hydroxypropyl cellulose were subjected to wet granulation using an efficient wet mixing granulator according to the ratio in Table 1. 3.4% hydroxypropyl methylcellulose and 2.3% sodium dodecyl sulfate aqueous solution were used as a granulation solution.
  • the dissolution of the tablets in Examples 1-7 was determined. 900ml 0.01mol/L hydrochloric acid solution was used as the dissolution medium and a dissolution test was conducted at a propeller speed of 50 rpm at 37 ⁇ 0.5 °C. The results showed that the compound TLTLO1101 in Examples 4, 6, and 7 had a slow dissolution rate and did not fully dissolve after 45 minutes. The compound TUL01101 in the other embodiments fully dissolved and had similar dissolution behavior.
  • cross-linked carboxymethyl cellulose sodium, carboxymethyl starch sodium, and cross-linked polyvinylketone are preferred as disintegrants.
  • TUL01101 is sensitive to moisture
  • cross-linked carboxymethyl cellulose sodium with relatively low moisture absorption is the most preferred disintegrant. Since increasing the dosage of disintegrant does not significantly improve the dissolution behavior, the optimal dosage of disintegrant is 8.0%.
  • the dissolution data is shown in Table 2, and the dissolution curve is shown in FIG. 1 .
  • the tablet of Example 1 was placed in a watch glass and conduct stability tests under high temperature (60 °C), high humidity (relative humidity 75% ⁇ 1%, 15.5-60 °C), and light (illumination 4500lx ⁇ 500lx) conditions. Samples were taken at 5 days, 10 days, and 30 days, respectively. The changes in related substances, content, and dissolution were determined using HPLC method. The results showed that the tablet of Example 1 had stable properties, and there was no significant difference of the influencing factors such as relevant substances, dissolution and content at 5th day, 10th day, and 30th day as compared with 0 day, data is shown in Table 3.
  • Example 1 The table of Example 1 was placed in an environment with a temperature of 40 °C ⁇ 2 °C and a relative humidity of 75% ⁇ 5% for stability evaluation. After being placed for one month, the changes of related substances, content, and dissolution were determined by HPLC method. The results showed that the tablet of Example 1 had stable properties, and the results were accelerated for one month compared to 0 day. There were no significant differences in relevant substances, dissolution, and content, data is shown in Table 4. Table 4 Test items 0 month 1 month Related substances (total impurities) 0.3% 0.3% Dissolution (30min) 99.1% 94.9% Content determination 99.7% 100.0%
  • the Crushed TUL01101, lactose, microcrystalline cellulose, and cross-linked carboxymethyl cellulose sodium were subjected to wet granulation using an efficient wet mixing granulator according to the ratio in Table 5.
  • 3.4% hydroxypropyl methyl cellulose or hydroxypropyl cellulose, polyvinylketone, and 2.3% sodium dodecyl sulfate aqueous solution were used as the granulation solution.
  • wet granulation and drying treatment were carried out, and then the dried particles (moisture ⁇ 3%) were size prepared under a dry condition, added externally with cross-linked sodium carboxymethyl cellulose and magnesium stearate, mixed well, and then tableted.
  • Table 5 Ingredients Examples (mg/tablet) 1 8 9 TUL01101 20.0 20.0 20.0 Lactose 78.5 78.5 78.5 Microcrystalline cellulose 78.5 78.5 78.5 Cross linked carboxymethyl cellulose sodium (added internally) 8.0 8.0 8.0 Hydroxypropyl methylcellulose 3.0 - - Hydroxypropyl cellulose - 3.0 - Povidone - - 3.0 Sodium dodecyl sulfate 2.0 2.0 2.0 Cross linked carboxymethyl cellulose sodium (added externally) 8.0 8.0 8.0 Magnesium stearate 2.0 2.0 2.0 tablet weight 200 200 200 200 200 200 200
  • the dissolution of the tablets in Examples 1 and 8-9 was determined. 900ml 0.01mol/L hydrochloric acid solution was used as the dissolution medium and a dissolution test was conducted at a propeller speed of 50rpm at 37 ⁇ 0.5 °C. The results showed that in Example 1, Example 8, and Example 9, TUL01101 completely dissolved and had similar dissolution behavior. Based on the research results of the above embodiments, the type of adhesives has no significant impact on the dissolution behavior of the formulation.
  • the dissolution data is shown in Table 6, and the dissolution curve is shown in FIG. 2 . Table 6 Time (min) Dissolution (%) 1 8 9 5 43.4 42.8 52.6 10 85.6 84.8 88.0 15 95.3 95.1 96.7 20 97.6 97.1 98.3 30 99.1 98.8 100.0 45 100.5 100.5 101.1
  • the crushed TUL01101, lactose, microcrystalline cellulose, pre-gelatinized starch, anhydrous dicalcium phosphate, and cross-linked carboxymethyl cellulose sodium were subjected to wet granulation using an efficient wet mixing granulator according to the ratio in Table 7. 3.4% hydroxypropyl methyl cellulose and 2.3% sodium dodecyl sulfate aqueous solution were used as granulation solution. After granulation, wet granulation and drying treatment are carried out, and then the dried particles (moisture ⁇ 3%) were subjected to dry size preparation, added externally with cross-linked sodium carboxymethyl cellulose and magnesium stearate, mixed well, and then tableted.
  • the dissolution of the tablets in Examples 1 and 10-13 was determined. 900ml 0.01mol/L hydrochloric acid solution was used as the dissolution medium and a dissolution test was conducted at a propeller speed of 50rpm at 37 ⁇ 0.5 °C. The results showed that in Example 12, compound TUL01101 slowly dissolved and could not completely dissolved, while in other embodiments, compound TUL01101 completely dissolved. Based on the research results of the above embodiments, the type and dosage of fillers will affect the dissolution behavior of the formulation. The dissolution data is shown in Table 8, and the dissolution curve is shown in FIG. 3 .
  • the crushed TUL01101, lactose, microcrystalline cellulose, and cross-linked carboxymethyl cellulose sodium were subjected to wet granulation using an efficient wet mixing granulator according to the ratio in Table 9. 3.4% hydroxypropyl methyl cellulose and 2.3% sodium dodecyl sulfate aqueous solution were used as the granulation solution. After granulation, wet granulation and drying treatment were carried out. Then, the dried particles (with a moisture content of less than 3%) were subjected dry size preparation, added externally with cross-linked carboxymethyl cellulose sodium and magnesium stearate, mixed well and tableted.
  • the dissolution of the tablets in Examples 1 and 14-18 was determined.
  • 900ml 0.01mol/L hydrochloric acid solution was used as the dissolution medium and a dissolution test was conducted at a propeller speed of 50rpm at 37 ⁇ 0.5 °C.
  • the results showed that in Example 18, compound TUL01101 had a slow dissolution, due to the excessive content of the main drug in a single dose of the formulation in Example 18, resulting in a slower dissolution behavior due to the limitation of the solubility of the main drug.
  • the dissolution behavior of other specifications of the formulation was similar.
  • the dissolution data is shown in Table 10, and the dissolution curve is shown in FIG.
  • the dissolution of the tablets in Example 1 and Example 19 was determined.
  • the dissolution data is shown in Table 12, and the dissolution curve is shown in FIG. 5 .
  • the results showed that in Example 19, compound TUL01101 was slowly dissolved and could not be completely dissolved.
  • the wet granulation process is preferred.
  • Table 12 Time (min) Dissolution (%) 1 19 5 43.4 59.8 10 85.6 76.8 15 95.3 82.4 20 97.6 84.5 30 99.1 86.4 45 100.5 88.4 60 - 88.7
  • Step 1 LiHMDS (1 M, 51.2 mL) was added dropwise to a THF (150 mL) solution containing compound 1-1 (10.2 g, 42.6 mmol) at -78 °C. The reaction solution was stirred at -78 °C for 1 hour, then THF (150 mL) solution of 1,1,1-trifluoro-N-phenyl-N-(trifluoromethyl sulfonyl group) methanesulfonamide (16.7 g, 46.9 mmol) was added to the reaction solution, and then stirred at 15 °C for 12 hours.
  • Step 2 potassium acetate (12.7 g, 129.3 mmol) and Pd (dppf) Cl2.CH2Cl2 (3.5 g, 4.3 mmol) were added to a DMF (100 mL) solution containing Compound 1-2 (16 g, 43.1 mmol) and pinacol diborate (12.0 g, 47.4 mmol). The solution was replaced with nitrogen three times and kept stirring at 70 ° C for 3 hours in a nitrogen atmosphere. The reaction solution was dispersed in a mixture of 300 mL of water and 400 mL of ethyl acetate. The organic phases were separated and washed with saturated salt water, dried with sodium sulfate, filtered and concentrated to obtain the crude product. The crude product was purified by silica gel chromatography to obtain Compound 1-3.
  • Step 3 In a nitrogen atmosphere, potassium carbonate (3.8 g, 27.3 mmol) and Pd (dppf) Cl2.CH2Cl2 (744 mg, 911.0 ⁇ mol) were added to a solution of Compound 1-3 (3.5 g, 10.0 mmol) and N-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropaneformamide (2.6 g, 9.1 mmol) dissolved in dioxane (60 mL) and water (15 mL). The reaction solution was stirred at 90 °C for 3 hours. The reaction solution was concentrated to obtain a crude product, which was separated and purified to obtain Compound 1-4 through column chromatography. LCMS (ESI) m/z: 324.1[M + H]+.
  • Step 4 hydrochloric acid/ethyl acetate (4 M, 30 mL) was added to a dichloromethane (10 mL) solution containing Compound 1-4 (3.5 g, 8.2 mmol), and stirred at 25 ° C for 0.5 hours. Solid was precipitated, filtered, and dried to obtain Compound 1-5 (3.3 g of hydrochloride, crude product), which was directly used for the next reaction without purification.
  • Step 5 Pd/C (1 g, 10%) was added to a methanol (100 mL) solution containing Compound 1-5 (3.0 g, 8.34 mmol, hydrochloride) in a nitrogen atmosphere. The suspension was replaced three times with hydrogen, and then stirred at 30 °C in hydrogen atmosphere (30 psi) for 12 hours. The reaction solution was filtered and concentrated to obtain Compound 1-6 (3 g of hydrochloride, crude product), which was directly used for the next reaction without purification.
  • Step 6 Compound 1-6 (0.87 g, 2.40 mmol, hydrochloride) was dissolved in N, N-dimethylformamide (10 mL), added with HOBt (487 mg, 3.6 mmol,) and EDCI (691 mg, 3.6 mmol), then added with (1S) -2,2-difluorocyclopropyl formic acid (323 mg, 2.6 mmol) and diisopropylethylamine (621 mg, 4.8 mmol), and reacted at 15 °C for 12 hours. The reaction solution was concentrated under reduced pressure, and the residue was obtained by preparative HPLC (neutral system) to obtain the compound of formula (II).
  • the crystal form A of the compound of formula (II) was heated to 170 °C. It was determined via XRPD detection (as shown in FIG. 11 ) that the crystal form was changed. The new crystal form obtained was crystal form C of the compound of formula (II), while DSC was further detected (as shown in FIG. 12 ).
  • Crystal form B was accurately weighed and placed in a dry and clean glass bottle, and spread into a thin layer to be used as a normal test sample. It was subjected to the influence factor test conditions (60 °C, 92.5% RH) and accelerated conditions (40 °C/75% RH and 60 °C/75% RH), and the sample was completely exposed. It was covered with aluminum foil and tie small holes. Sampling was taken for analysis at 5th day and 10th day. The sample placed under light conditions (visible light 1200000Lux, UV 200W) was fully exposed at room temperature.
  • sample crystal form B was weighed and placed into the sample bottle, and then added with 1.0 mL of different solvents [pure water, SGF (simulating gastric juice), FaSSIF (simulating intestinal fluid in fasting state), FeSSIF (simulating intestinal fluid in eating state)] in each bottle, and shaken well. It was placed on a constant temperature oscillator and shaken at 37 °C. After shaking for 24 hours, centrifuging was performed to obtain supernatant, which was separated and tested in terms of solubility.
  • solvents pure water, SGF (simulating gastric juice), FaSSIF (simulating intestinal fluid in fasting state), FeSSIF (simulating intestinal fluid in eating state)
  • the supernatant (diluent ACN/H2O (1/1)) was diluted by a certain times (the solubility of the compound was low, and the supernatant was diluted twice except for SGF, and SGF was diluted 10 times), and the concentration was determined by using HPLC.
  • Diluent acetonitrile: water of 1:1.
  • Mobile phase A 0.1% TFA aqueous solution, for example: 1 mL of TFA was transferred into 1 L of pure water, mixed well, and degased by ultrasound.
  • Mobile phase B 100% acetonitrile.
  • STD solution crystal form B was used as the reference substance. Approximately 5 mg of the reference substance was weighed and added into a glass bottle, dissolved with 10 mL of diluent, sonicated for about 10 minutes to fully dissolve the sample, cooled to room temperature, and shaken well. Two copies were prepared in parallel and labeled as corresponding STD1 and STD2. The corresponding STD1 was diluted by diluent 10, 100, 1000, and 2000 times, and a standard curve was obtained for testing.
  • sample solution the supernatant (diluent ACN/H2O (1/1)) was diluted by a certain time (the solubility of the compound is small, and the supernatant is diluted twice except for SGF, and SGF was diluted by 10 times), shaken well, and placed it in a 1.5 mL liquid phase vial for testing.
  • concentration was determined by using HPLC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP22745081.4A 2021-01-29 2022-01-17 Préparation orale contenant un inhibiteur de jak ou un sel de celui-ci ou une forme cristalline de celui-ci, son procédé de préparation et son application Pending EP4285899A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110114769 2021-01-29
PCT/CN2022/072415 WO2022161205A1 (fr) 2021-01-29 2022-01-17 Préparation orale contenant un inhibiteur de jak ou un sel de celui-ci ou une forme cristalline de celui-ci, son procédé de préparation et son application

Publications (1)

Publication Number Publication Date
EP4285899A1 true EP4285899A1 (fr) 2023-12-06

Family

ID=82653047

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22745081.4A Pending EP4285899A1 (fr) 2021-01-29 2022-01-17 Préparation orale contenant un inhibiteur de jak ou un sel de celui-ci ou une forme cristalline de celui-ci, son procédé de préparation et son application

Country Status (8)

Country Link
US (1) US20240033255A1 (fr)
EP (1) EP4285899A1 (fr)
JP (1) JP2024504483A (fr)
KR (1) KR20230129248A (fr)
CN (1) CN116724039A (fr)
AU (1) AU2022214702A1 (fr)
CA (1) CA3210023A1 (fr)
WO (1) WO2022161205A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4108664A4 (fr) * 2020-02-21 2024-03-06 Zhuhai United Laboratories Co Ltd Forme cristalline d'inhibiteur de jak et son application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6978098B2 (ja) * 2016-07-26 2021-12-08 スーヂョウ ロングバイオテック ファーマシューティカルズ カンパニー リミテッドSuzhou Longbiotech Pharmaceuticals Co., Ltd. 選択的ｊａｋ阻害剤としての化合物、該化合物の塩類および治療への使用
CN108341814B (zh) * 2017-01-23 2021-09-03 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用
PL3842431T3 (pl) 2018-08-23 2024-05-20 Zhuhai United Laboratories Co., Ltd. Związek [1,2,4]triazolo[1,5-a]pirydyny jako inhibitor jak i jego zastosowanie
CN111892592B (zh) * 2019-08-06 2023-09-19 江苏柯菲平医药股份有限公司 Jak激酶抑制剂及其用途
KR20220127900A (ko) * 2020-02-13 2022-09-20 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 Jak 키나아제 관련 질병의 치료를 위한 약물의 제조에 있어서 jak 억제제의 용도
CN115038701B (zh) * 2020-02-21 2023-06-16 珠海联邦制药股份有限公司 Jak抑制剂的晶型及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4108664A4 (fr) * 2020-02-21 2024-03-06 Zhuhai United Laboratories Co Ltd Forme cristalline d'inhibiteur de jak et son application

Also Published As

Publication number Publication date
CA3210023A1 (fr) 2022-08-04
WO2022161205A1 (fr) 2022-08-04
JP2024504483A (ja) 2024-01-31
CN116724039A (zh) 2023-09-08
US20240033255A1 (en) 2024-02-01
AU2022214702A1 (en) 2023-08-03
KR20230129248A (ko) 2023-09-07

Similar Documents

Publication Publication Date Title
CN102421784B (zh) 作为gsk-3抑制剂的7-环烷基氨基喹诺酮
AU2013257516B2 (en) (Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
CN102448444B (zh) 包括硝基儿茶酚衍生物的药物制剂及其制备方法
EP2589384A1 (fr) Nouvelles compositions pharmaceutiques pour le traitement de troubles hyper-prolifératifs
US10537524B2 (en) Apixaban solid composition and preparation method thereof
EP3675863A1 (fr) Composition pharmaceutique comprenant de la sépiaptérine et ses utilisations
SK369292A3 (en) Orally administerable drugs for the treatment of central dopamine deficiency conditions
KR20140087846A (ko) 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법
TW200539879A (en) Pharmaceutical dosage forms and compositions
EP4285899A1 (fr) Préparation orale contenant un inhibiteur de jak ou un sel de celui-ci ou une forme cristalline de celui-ci, son procédé de préparation et son application
CN106794182A (zh) 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
AU2019378161A1 (en) Crystalline forms of a substituted imidazopyridine compound and use thereof as P2x3 modulator
RU2770081C2 (ru) Композиции и способы для лечения рака
CN103610658A (zh) 一种免疫调节剂缓释剂及其制备方法
CN112933049B (zh) 含无定型态芳杂环化合物的组合物、其制备方法及用途
CN113509447B (zh) 一种具有ido抑制活性的缓释片及其制备方法和应用
CN109937203A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
CA3207049A1 (fr) Agents de degradation d'irak4 et leurs utilisations
EP3603643B1 (fr) Composition médicinale en comprimés comprenant de la nalfurafine
JP2001213890A (ja) トレハロース粒子
CN109700778B (zh) 一种盐酸西那卡塞速释制剂及其制备方法
CN107661506B (zh) 枸橼酸莫沙必利的药物制剂及其制备方法
JP2007297348A (ja) エバスチンを含有する錠剤
CN106389361A (zh) 一种含有雷美替胺的口腔崩解片及其制备方法
CN112220785A (zh) 一种pde4抑制剂药物组合物及其制备方法与用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)